Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019254 | 1.00 | ACACB (0.36) | ACACBACACACA1BLMKISS1R | |
| SCHEMBL996508 | 0.84 | ALDH1A1 (0.39) | ACACBACACACA1BLMKISS1R | |
| SCHEMBL12153331 | 0.82 | CA1 (0.48) | CA1BLMKISS1RLTA4HGABRR1 | |
| SCHEMBL20825612 | 0.81 | BLM (0.54) | ACACBACACACA1BLMLTA4H | |
| SCHEMBL12153332 | 0.79 | CA1 (0.46) | ACACBACACACA1BLMLTA4H | |
| SCHEMBL25939092 | 0.79 | ACACB (0.35) | ACACBACACACA1BLMLTA4H | |
| SCHEMBL9580 | 0.79 | CA1 (0.39) | ACACBACACACA1BLMLTA4H | |
| SCHEMBL2692582 | 0.79 | ALDH1A1 (0.44) | ACACBACACACA1BLMKISS1R | |
| SCHEMBL15383712 | 0.78 | ACACB (0.33) | ACACBACACAKISS1R | |
| SCHEMBL17431017 | 0.77 | LTA4H (0.50) | ACACBACACACA1BLMLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | ACACB 2448/4885ACACA 2612/4885CA1 4847/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | ACACB 2448/4885ACACA 2612/4885CA1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.